Ocular ischaemic complications in giant cell arteritis: CHADS2-score predicts risk of permanent visual impairment.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Historique:
received: 03 12 2018
accepted: 18 02 2019
entrez: 5 6 2019
pubmed: 5 6 2019
medline: 15 6 2019
Statut: ppublish

Résumé

To identify independent risk factors for permanent visual loss (PVL) in patients with giant cell arteritis (GCA), with a special focus on sonographic findings of the temporal, carotid and subclavian/axillary arteries, and on established scoring systems of ischaemia risk assessment. Consecutive patients with a diagnosis of GCA between 2002 and 2013 were retrospectively identified from a prospectively maintained database. Data on clinical characteristics including ophthalmological findings, laboratory values, and sonographic findings of the temporal, carotid an axillary arteries were extracted. CHADS2- and CHA2DS2-VASc-score were calculated. Clinical, laboratory and sonographic characteristics of patients with and without PVL were compared. Multiple logistic regression models were calculated to identify variables independently associated with PVL. One-hundred-fifty-two patients were included in the analysis. PVL occurred in 30.2% of patients, with anterior ischaemic optic neuropathy as predominant underlying cause (91.3%). The frequency of PVL was strongly dependent on the age at diagnosis, with a significant increase after the age of 70 years. In multivariate analysis, axillary artery vasculitis with an odds ratio (OR) of 0.3 and constitutional symptoms with an OR of 0.1 were negatively associated with PVL. A CHADS2-score of 1 (OR 10.7) or ≥2 (OR 25) was associated with a significantly increased risk of PVL. The risk of PVL secondary to GCA increases with age but is lower in patients presenting with constitutional symptoms and/or exhibiting axillary artery involvement. The CHADS2-score may help to discriminate patients with low vs. high risk of PVL.

Identifiants

pubmed: 31162028
pii: 13718

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

61-64

Auteurs

Michael Czihal (M)

Division of Vascular Medicine, Medical Clinic and Policlinic IV, University Hospital, Ludwig-Maximilians-University, Munich, Germany. michael.czihal@med.uni-muenchen.de.

Janina Tschaidse (J)

Division of Vascular Medicine, Medical Clinic and Policlinic IV, University Hospital, Ludwig-Maximilians-University, Munich, Germany.

Christoph Bernau (C)

Division of Vascular Medicine, Medical Clinic and Policlinic IV, University Hospital, Ludwig-Maximilians-University, Munich, Germany.

Christian Lottspeich (C)

Division of Vascular Medicine, Medical Clinic and Policlinic IV, University Hospital, Ludwig-Maximilians-University, Munich, Germany.

Anton Köhler (A)

Division of Vascular Medicine, Medical Clinic and Policlinic IV, University Hospital, Ludwig-Maximilians-University, Munich, Germany.

Claudia Dechant (C)

Division of Rheumatology and Clinical Immunology, Medical Clinic and Policlinic IV, University Hospital, Ludwig-Maximilians-University, Munich, Germany.

Hendrik Schulze-Koops (H)

Division of Rheumatology and Clinical Immunology, Medical Clinic and Policlinic IV, University Hospital, Ludwig-Maximilians-University, Munich, Germany.

Ulrich Hoffmann (U)

Division of Vascular Medicine, Medical Clinic and Policlinic IV, University Hospital, Ludwig-Maximilians-University, Munich, Germany.

Marc J Mackert (MJ)

Department of Ophthalmology, University Hospital, Ludwig- Maximilians-University, Munich, Germany.

Stephan Thurau (S)

Department of Ophthalmology, University Hospital, Ludwig- Maximilians-University, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH